Drug Trial Radar · NCT01986933
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
Last checked: Nov 20, 2026Latest source record: Jan 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Nov 2013
Primary completion
Apr 2015
Study completion Jun 2016
Sponsor
- Lead sponsor
- Chugai PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
Conditions
- Atopic Dermatitis
Interventions
nemolizumab (CIM331)Drug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12Time frame: baseline to Week 12
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Anniston, Alabama
Site not named
San Diego, California
Site not named
Miami, Florida
Site not named
Alpharetta, Georgia
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Louisville, Kentucky
Site not named
Louisville, Kentucky
Site not named
Bay City, Michigan
Site not named
New York, New York
Site not named
Charlotte, North Carolina
Site not named
Cleveland, Ohio
Site not named
Portland, Oregon
Site not named
Charleston, South Carolina
Site not named
Charleston, South Carolina
Site not named
College Station, Texas
Site not named
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.